摘要
为探讨血清特异性microRNA与直肠癌新辅助放化疗有效性之间的关系,收集2015年6月至2016年6月于甘肃省人民医院肛肠外科接受新辅助放化疗的局部晚期直肠癌患者的资料,选取符合标准的18例,患者均于新辅助放化疗1个周期后通过影像学检查评估新辅助放化疗的有效性和无效性,并基于基因芯片技术分别对相应患者的18份血清标本进行基因测序.结果显示,新辅助放化疗有效组（6例）和无效组（12例）相比,共筛选得到显著上调基因217个,下调基因73个,无显著差异基因1 162个,其中差异倍数≥5.0000的上调基因26个,差异倍数≥0.3000的下调基因26个.结果表明,血清microRNA可用来评估直肠癌新辅助放化疗的有效性,并且差异表达的血清microRNA在直肠癌预后评估及治疗效果评价等方面具有广阔的临床应用价值.
In order to explore the relationship between serum specific microRNA and the effectiveness of neoadjuvant chemoradiotherapy（nCRT） for rectal cancer, 18 patients with locally advanced rectal cancer who received nCRT in the Colorectal Surgery Department of Gansu People＇s Hospital were collected from June 2015 to June 2016. After one period of nCRT,the effectiveness and ineffectiveness of nCRT were eval- uated by the imaging examination~ Gene sequencing of 18 serum samples was carried out respectively by gene chip technology.As results,compared between the effective group（6 cases） and ineffective groups（12 cases） of nCRT there were 217 obvious up-regulated and 73 down-regulated of microRNA after scanning there were 1162 genes without obvious difference among them, there were 26 up-regulated genes（fold change ≥5.0 000） and 26 down-regulated genes（fold change≥0.3 000）.Results show that the serum microRNA can be used to evaluate the effectiveness of nCRT for rectal cancer,and the differential expression of serum microRNA has a wide clinical value in the evaluation of prognosis and treatment for rectal cancer.
出处
《中国肛肠病杂志》
2017年第8期7-10,共4页
Chinese Journal of Coloproctology
基金
兰州市人才创新创业项目（2015-RC-37）
